BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Memento EPFL// BEGIN:VEVENT SUMMARY:U.S. CDMRP – Breast Cancer Research Program | Research Funding DTSTART;VALUE=DATE:20260612 DTSTAMP:20260526T170126Z UID:010c7658610346ffbf7f67c5ba030a655e053821aa8b04e20d9f6c36 CATEGORIES:Call for proposal DESCRIPTION:Aim: Through the Congressionally Directed Medical Research Pro gram (CDMRP)\, the Department of Defense is announcing the 2026 Breast Can cer Research Program (BCRP) Awards. Several award programs are available:\ n\n The Breakthrough Awards supports promising research that has high pote ntial to lead to or make breakthroughs in breast cancer. The Breakthrough Award is structured with four different funding levels. Each level has a d efined research scope :\n \n Funding Level 1: Innovative\, high-risk/hig h-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem.\n Funding Level 2: Research that is already supported by substantial preliminary or publis hed data and strongly validates clinical translation in a well-defined con text within the breast cancer landscape.\n Funding Level 3: Advanced tran slational studies with a high degree of project readiness.\n Funding Leve l 4: Large-scale projects that will transform and revolutionize the clinic al management and/or prevention of breast cancer. Human clinical trials ar e required.\n \n \n The Clinical Research Extension Award aims to extend t he data collection\, follow-up\, and analysis of breast cancer clinical re search studies. Proposed research may entail a deeper molecular analysis o f clinical samples\, initiation of new correlative studies\, biomarker val idation\, or continuing clinical follow-up of patients currently/previousl y enrolled in an open/ongoing or completed clinical trial.\n The Era of Ho pe Scholar Award supports individuals early in their careers who have demo nstrated significant potential to effect meaningful change in breast cance r. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s)\n The T ransformative Breast Cancer Consortium Award is designed to support large- scale\, multidisciplinary and multi-institutional consortia that address m ajor challenges in breast cancer through tightly integrated and collaborat ive research efforts. It enables up to five Principal Investigators\, incl uding a Consortium Director\, to work within a coordinated framework where all project components are aligned toward a shared central hypothesis. Th e award specifically aims to foster innovative and paradigm-shifting appro aches that go beyond the capabilities of individual laboratories\, requiri ng strong integration across scientific\, administrative\, and logistical aspects\, as well as the active involvement of breast cancer advocates and cross-disciplinary expertise.\n The Transformative Breast Cancer Consorti um Development Award is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates t ogether to establish a consortium framework and conduct preliminary resear ch to support application to a future\, full Transformative Breast Cancer Consortium Award (pending availability of funds). This is a development aw ard and is a separate mechanism from the full consortium award. Recipients of the FY26 Transformative Breast Cancer Consortium Development Award are expected to submit an application to compete for the full Transformative Breast Cancer Consortium Award anticipated to be offered in a future fisca l year(s).\n\n\nAll applications must align with at least one BCRP Overarc hing Challenge. The FY26 BCRP Challenges are listed at the end of this ann ouncement.\n\nFunding:      \nBreakthrough 1: $750K - $1.25M\nBreakth rough 2: $1.65M - $3.35M\nBreakthrough 3: $5.6M - $7M\nBreakthrough 4: max . $21M\nClinical Research Extension: $7M - $8.4M\nEra of Hope: max. $4.9M\ nTransformative Breast Cancer Consortium Award: max. $35M\nTransformative Breast Cancer Consortium Development Award: max. $140K\nNote: Cost caps ar e total costs (direct plus indirect costs). In accordance with EPFL guid elines\, budgets should include a 20% overhead\, and the total budget must remain within the grant’s maximum allowable funding.\n\nDuration:      \nBreakthrough 1: 3 years\nBreakthrough 2: 3-4 years\nBreakthrough 3: 4 years\nBreakthrough 4: 4 years\nClinical Research Extension: 4 years\nEr a of Hope: 4 years\nTransformative Breast Cancer Consortium Award: 4 years \nTransformative Breast Cancer Consortium Development Award: 1 year\n\nEli gibility: Applicants from international organizations or institutions are eligible to apply\, and there are no citizenship restrictions. Programme-s pecific seniority levels are further defined here.\n\nHow to Apply: Pre-ap plications are submitted through the eBRAP platform. They should contain c ontact information\, a letter of intent\, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.\n\nPre-Application Deadline:             \n\n\n 12 June 2026\, 5:00 p.m. Eastern time\n\n \n Breakthrough Awa rd Level 3\n Breakthrough Award Level 4\n Transformative Breast Cancer C onsortium Award\n \n \n 24 June 2026\, 5:00 p.m. Eastern time\n \n Breakt hrough Award Level 1-2\n Transformative Breast Cancer Consortium Developm ent Award\n Clinical Research Extension Award\n Era of Hope Scholar Awar d\n \n \n\n\nFull Application Deadline:          \n\n\n 08 July 2 026\, 11:59 p.m. Eastern time\n\n \n Breakthrough Award Level 1-2\n Tran sformative Breast Cancer Consortium Development Award\n Clinical Research Extension Award\n Era of Hope Scholar Award\n \n \n 30 September 2026\, 11:59 p.m. Eastern time\n \n Breakthrough Award Level 3\n Breakthrough A ward Level 4\n Transformative Breast Cancer Consortium Award\n \n \n\n\nF urther information:\n\n\n To find the full program announcements and to st art your pre-application see here\n A useful summary of each call can be f ound here\n For questions about the eBRAP or Grants.gov platforms\, contac t the Research Office.\n Grants.gov Funding Opportunity Numbers:\n \n Bre akthrough 1: HT942526BCRPBTA12\n Breakthrough 2: HT942526BCRPBTA12\n Bre akthrough 3: HT942526BCRPBTA3\n Breakthrough 4: HT942526BCRPBTA4\n Clini cal Research Extension: HT942526BCRPCREA\n Era of Hope: HT942526BCRPEOHS\ n Transformative Breast Cancer Consortium Award: HT942526BCRPTBCCA\n Tra nsformative Breast Cancer Consortium Development Award: HT942526BCRPTBCCDA \n \n \n\n\nFY26 BCRP Overarching Challenges\n\n\n Prevent breast cancer ( primary prevention)\n Identify determinants of breast cancer initiation\, risk\, or susceptibility\n Distinguish deadly from non-deadly breast cance rs\n Conquer the problems of overdiagnosis and overtreatment\n Identify wh at drives breast cancer growth\; determine how to stop it\n Identify why s ome breast cancers become metastatic\n Determine why/how breast cancer cel ls lie dormant for years and then re-emerge\; determine how to prevent let hal recurrence\n Revolutionize treatment regimens by replacing them with o nes that do all of the following: improve survival\, are more effective\, and are less toxic\n Eliminate the mortality associated with metastatic br east cancer\n\nAlternatively\, with adequate justification\, applications may identify and address another overarching challenge related to The Brea st Cancer Landscape. Justification must be provided in the application.\n   LOCATION: STATUS:CONFIRMED END:VEVENT END:VCALENDAR